Coherent sees new laser as standard treatment for glaucoma:
This article was originally published in Clinica
In a pilot study of its new Selecta 7000 laser, Coherent found that it reduced the pressure associated with open-angle glaucoma by 30% on the first day of treatment, and that the benefit lasted for one year of follow-up. These initial results have encouraged the company to believe its technique, selective laser traberculoplasty, could become a standard treatment. The company is to begin shipment of the laser outside the US and will pursue clinical investigations in the US and Japan.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.